A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Affiliated Hospital to Academy of Military Medical Sciences
City of Hope Medical Center
University of Leeds
University of Leeds
Oncotherapeutics
Celyad Oncology SA
Second Affiliated Hospital, School of Medicine, Zhejiang University
Thomas Jefferson University
GlaxoSmithKline
University of Athens
Masonic Cancer Center, University of Minnesota
Hebei Senlang Biotechnology Inc., Ltd.
Case Comprehensive Cancer Center
Roswell Park Cancer Institute
University of Maryland, Baltimore
University of Maryland, Baltimore
University of Maryland, Baltimore
Icahn School of Medicine at Mount Sinai
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fondazione EMN Italy Onlus
Masonic Cancer Center, University of Minnesota
University Hospital Tuebingen
OHSU Knight Cancer Institute
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Dana-Farber Cancer Institute
University of Rochester
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Roswell Park Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Northwestern University
OHSU Knight Cancer Institute
University of Arkansas
Case Comprehensive Cancer Center
University of Arkansas
Case Comprehensive Cancer Center
Fred Hutchinson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins